Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06801591 plus BCG versus BCG in high-risk BCG-naïve non–muscle invasive bladder cancer
2019-003375-19Phase 3Active
- Sponsor
- Pfizer
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sasanlimab in bladder cancer (3 arms), sponsored by Pfizer. Primary endpoint: Event-free survival (EFS). Started Apr 2020; status: active.
02
Drugs
sasanlimab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2019-003375-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003375-19.